| 侯丽娟,王文文,翟建军,等.宫颈癌病人切除修复交叉互补基因 1基因多态性与铂类超敏反应关系[J].安徽医药,2022,26(3):549-553. |
| 宫颈癌病人切除修复交叉互补基因 1基因多态性与铂类超敏反应关系 |
| Relationship between excision repair cross-complementation group 1 gene polymorphism and platinum hypersensitivity in patients with cervical cancer |
| |
| DOI：10.3969/j.issn.1009-6469.2022.03.030 |
| 中文关键词: 宫颈肿瘤 切除修复交叉互补基因 1基因多态性 铂类超敏反应 CT基因型 CC基因型 淋巴结转移 间质浸润 |
| 英文关键词: Uterine cervical neoplasms ERCC1 gene polymorphism Platinum-based hypersensitivity CT genotype CC genotype Lymph node metastasis Interstitial invasion |
| 基金项目: |
|
| 摘要点击次数: 1414 |
| 全文下载次数: 562 |
| 中文摘要: |
| 目的探究宫颈癌病人切除修复交叉互补基因 1(excision repair cross complement 1，ERCC1)基因多态性与铂类超敏反应关系及其危险因素。方法选取 2012年 1月至 2017年 9月首都医科大学附属北京同仁医院收治的 103例宫颈癌病人作为研究对象，均接受以铂类为基础的联合化疗， 21 d为 1个化疗周期，化疗 1~2周期后，统计化疗效果，以此分为敏感组( n=71)和耐药组( n=32)，统计两组 ERCC1 rs11615位点基因型分布及 logistic回归分析宫颈癌铂类化疗敏感性与临床病理参数的关系，比较不同 ERCC1 rs11615位点基因型分布中位无进展生存期( PFS)。结果(1)敏感组 ERCC1 rs11615位点 CT基因型 |
| 英文摘要: |
| Objective To explore the relationship between excision repair cross-complementation group 1 (ERCC1) gene polymorphisms and platinum hypersensitivity reaction and its risk factors in patients with cervical cancer.Methods A total of 103 cervical cancer patients admitted to Beijing Tongren Hospital, CMU from January 2012-September 2017 were selected as the research subjects. All patients received platinum-based combination chemotherapy in a 21-day cycle. After one to two cycles of chemotherapy, the effectsof chemotherapy were calculated, and the patients were divided into a sensitive group (n=71) and a resistant group (n=32). The genotype distribution of ERCC1 rs11615 in the two groups was calculated, the relationship between platinum chemotherapy sensitivity andthe clinical pathological parameters of cervical cancer was analyzed by logistic regression, and the median progression-free survival (PFS) of ERCC1 rs11615 locus genotype distribution was compared.Results (1) The CT genotype of the ERCC1 rs11615 locus in the sensitive group was 64.79% higher than that in the drug-resistant group (18.75%), and the risk of chemotherapy resistance in cervicalcancer patients with the CT genotype of the ERCC1 rs11615 loci was lower than that in the CC genotype (P<0.05). (2) Clinical stage Ⅳ,ERCC1 rs11615 CC genotype, lymph node metastasis, deep interstitial invasion, and low degree of differentiation were closely relatedto the sensitivity of platinum-based chemotherapy to cervical cancer (P<0.05). (3) Clinical stage Ⅳ (OR=3.95), ERCC1 rs11615 CC genotype (OR=4.31), lymph node metastasis (OR=3.98), deep interstitial invasion (OR=6.82), and low degree of differentiation (OR= 4.85) are risk factors affecting platinum chemotherapy sensitivity of cervical cancer (P<0.05). (4) Log-rank analysis showed that therewas no significant difference in the median PFS (9.8 months) and CT genotype (10.9 months) of the CC genotype at ERCC1 rs11615 (P> 0.05).Conclusions Platinum hypersensitivity in cervical cancer patients is related to the ERCC1 rs11615 genotype, clinical stage,lymph node metastasis, and degree of differentiation. It is recommended to observe the above indicators in clinical practice to provideguidance for the differential diagnosis of cervical cancer platinum-chemotherapy hypersensitivity. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
